CytomX Therapeutics Inc (CTMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has a cash flow conversion efficiency ratio of -0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.55 Million) by net assets ($319.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CTMX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
CytomX Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how CytomX Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CytomX Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CytomX Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Chippacking Technology Co. Ltd. A
SHG:688216
|
N/A |
|
Bomesc Offshore Engineering Co
SHG:603727
|
0.021x |
|
mobilezone ag
SW:MOZN
|
-1.383x |
|
Shaanxi Kanghui Pharm Co Ltd
SHG:603139
|
0.012x |
|
DCB Bank Limited
NSE:DCBBANK
|
-0.040x |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
0.111x |
|
Beibu Gulf Tourism Corp Ltd
SHG:603869
|
0.033x |
|
Patrizia AG
XETRA:PAT
|
0.038x |
Annual Cash Flow Conversion Efficiency for CytomX Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of CytomX Therapeutics Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see CytomX Therapeutics Inc (CTMX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $99.01 Million | $-75.59 Million | -0.763x | -100.40% |
| 2024-12-31 | $-456.00K | $-86.23 Million | 189.103x | +15912.09% |
| 2023-12-31 | $-47.45 Million | $-56.03 Million | 1.181x | -8.59% |
| 2022-12-31 | $-85.75 Million | $-110.79 Million | 1.292x | +197.01% |
| 2021-12-31 | $89.38 Million | $-119.03 Million | -1.332x | -96.86% |
| 2020-12-31 | $-7.77 Million | $5.26 Million | -0.676x | +75.39% |
| 2019-12-31 | $51.11 Million | $-140.48 Million | -2.748x | -376.32% |
| 2018-12-31 | $130.88 Million | $-75.52 Million | -0.577x | -123.67% |
| 2017-12-31 | $69.90 Million | $170.37 Million | 2.438x | +9514.09% |
| 2016-12-31 | $78.48 Million | $-2.03 Million | -0.026x | +88.09% |
| 2015-12-31 | $126.07 Million | $-27.41 Million | -0.217x | +46.29% |
| 2014-12-31 | $-78.54 Million | $31.80 Million | -0.405x | -323.89% |
| 2013-12-31 | $-44.28 Million | $-8.01 Million | 0.181x | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell… Read more